Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of intermittent duvelisib dosing in indolent non-Hodgkin lymphoma
2019-001381-14Phase 2Completed
- Sponsor
- Verastem Oncology
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of duvelisib in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Verastem Oncology. Primary endpoint: Overall response rate (Cheson 2007). Started Aug 2019; status: completed.
02
Drugs
duvelisib
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2019-001381-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001381-14.